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Abstract
We present two families, from Spain and Portugal, with familial amyloid polyneuropathy (FAP) associated with the mutation
TTRSer50Arg. This mutation was first described in two Japanese patients from independent families and later in a French-
Italian patient and a Vietnamese family. The two families presented here, are the first to be diagnosed with this mutation in
the Iberian Peninsula. In the patients of both families, FAP was very aggressive as they rapidly developed multiple symptoms
with progressive deterioration; we emphasize the presence of severe orthostatic hypotension in the Spanish proband which
confined him to a wheelchair. This proband was the first patient with this mutation to have undergone liver transplantation
and results were encouraging. The mutation was detected in four patients and one disease-free relative by DNA sequencing
of exon 3 and induced mutation restriction analysis. The most outstanding feature was the single base transversion A to C in
codon 50 (CGT instead of AGT), whereas in both Japanese patients and the French-Italian patient it was T to G (AGG
instead of AGT). To our knowledge only six FAP mutations with more than one single nucleotide mutation for the same
codon have been reported to date.
Introduction
Familial amyloid polyneuropathy (FAP) is a late-
onset inherited amyloidosis associated with a muta-
tion on the transthyretin (TTR) gene which codes for
a TTR variant. Large foci of FAP related to a parti-
cular variant TTR with a methionine for valine
substitution at position 30 (TTRVal30Met) have
been described in Portugal, Japan, Sweden, Brazil
and the Balearic Islands. Besides these foci, isolated
affected families have been described all over the
world, some related to TTRVal30Met or to other
TTR variants. More than 80 different pathogenic
variants have been described [1].
One recently described pathogenic mutation is
TTRSer50Arg. It was previously reported in two
Japanese patients from independent families [2,3], in
a French-Italian patient [4] and in a Vietnamese
family [5].
We present the clinical and genetic data of one
Spanish and two Portuguese TTRSer50Arg patients,
together with short clinical reports on affected relatives
of the former. We include the pedigrees in Figures 1
and 2, the symbols for which are shown in Table I.
These are the first families with this mutation in
the Iberian Peninsula and the second and third in the
Caucasian population.
Case reports
Spanish patients
Proband. The patient, a 42-year-old man born in
Jae´n, Spain, started with progressive anorexia, loss of
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weight and vitality, depression and muscular weak-
ness of distal portions of lower limbs with slight
difficulty in walking without steppage.
In the following 12 months his weight loss reached
40 kg. During this interval he developed: (i) pro-
gressive severe orthostatic hypotension (OH), with
frequent bouts of postural syncope requiring con-
finement to a wheelchair; (ii) distal paresthesia in the
four limbs; (iii) constipation which later alternated
with progressively more frequent diarrhea; and
(iv) sexual impotence.
At age 43 he was visited for the first time. An
electromyography showed a chronic axonal poly-
neuropathy (PNP) affecting predominantly sensory
nerves in the lower limbs. Rectal biopsy with prior
Congo red staining (CR) revealed amyloid de-
position positively stained with anti-TTR serum
Figure 1. Pedigree of the Spanish family. See Table I for definitions of symbols.
Figure 2. Pedigree of the Portuguese family. See Table I for definitions of symbols.
Table I. Symbols of pedigrees.
Non affected
Non-affected, unknown sex
Confirmed patient
Patient with DNA analysis
Non-carrier of the mutation
Asymptomatic carrier of
the mutation
Deceased
& Proband
a.o. Age at onset
a.d. Age at death
a. Present age
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confirming the diagnosis of FAP. Finally, a genetic
study was performed.
To halt the progression of FAP, a liver transplan-
tation (LTX) was indicated. It was performed in
June 2000, 9 months after the first visit and 2 years
from the onset of the disease. Graft function to date
is excellent. A direct enzyme-linked immunosorbent
assay (ELISA) with the monoclonal antibody
Mab39-44 [6], showed the disappearance of the
variant in plasma. Furthermore, several significant
changes in the clinical picture were observed starting
1 year after LTX. First, following a slow, but pro-
gressive improvement of OH, in 2003 the patient was
able to leave the wheelchair and gradually returned
to work; since 2004 he has been working part-time.
Second, distal paresthesias decreased. Third, amyo-
trophy and weakness of lower limbs was improved
and he has gradually been able to increase walking
time. Fourth, his appetite has improved without
weight gain and, finally, since 2003 the diarrhea has
disappeared. The patient is satisfied with the result of
LTX as he is leading an active life with part-time
work; this explains his reticence to periodic check-
ups at the hospital.
The patient has four siblings aged 40, 38, 36 and
33 years, and three offspring aged 21, 17 and 12
years, all asymptomatic; they refused the genetic
study.
Patient II-2. A 48-year-old man presented with
progressive PNP in the lower limbs, weakness and
weight loss. Rectal biopsy showed amyloid
deposits detected by CR. He died aged 52 with
cachexia.
Patient II-3. A 45-year-old woman, mother of the
proband, presented with a clinical picture similar
to her son’s except for the severe OH. In a sural
nerve biopsy amyloid deposits were detected by
CR. After progressive deterioration she died at
age 48.
Patient II-5. A 53-year-old man presented with pro-
gressive vitreous deposits in both eyes, without
systemic symptoms. He underwent right vitrectomy
aged 59 years; amyloid was detected by CR in these
deposits. A genetic study was performed. Eight years
later, still without systemic symptoms, he underwent
left vitrectomy. He died of lung cancer aged 68. After
his death a genetic study was performed in one
offspring.
Patient II-7. A 40-year-old man presented with a
clinical picture similar to his sib II-2. He was also
diagnosed with FAP after detection of amyloid
deposits by CR in rectal biopsy. He died aged 46
years at a very advanced stage.
Portuguese patients
Proband. At 48 years of age, this Portuguese man
suffered right sciatic syndrome due to lumbar disc
herniation which was relieved with surgery. A few
months later he complained of neuralgic pain in
both legs and feet, followed 1 year later by sexual
impotence and urinary retention with vesical large
residue. He was operated on again without any
improvement. In addition to the previous symptoms
he developed anorexia, weight loss, vomiting after
meals, constipation alternating with diarrhea and
difficulty in walking and using his hands. An electro-
myography showed a severe axonal neuropathy,
affecting sensory and motor divisions of the nerves
in the upper and lower limbs. In a rectal biopsy
amyloid deposits were detected by CR which stained
with anti-TTR serum.
At age 50 he was visited for the first time. He was a
thin, wheelchair-bound man with a severe amyo-
trophic tetraparesis, unable to walk. He had pain and
tactile anesthesia in all four limbs, and OH. He
denied any family history but he informed us that
his mother was also disabled due to a presumed
rheumatic disease. A genetic study was performed on
the patient and his three asymptomatic relatives.
During the next year he had severe episodes of
syncope. An electrocardiogram showed III-degree
atrioventricular block; a pacemaker was implanted
and the loss of consciousness episodes were con-
trolled. An echocardiogram was considered normal.
He died at age 53, with cachexia.
Patient II-3. This was the patient’s mother. At 59
years of age she also suffered a sciatic syndrome due
to lumbar disc herniation, and successfully under-
went surgery. At 68 years of age she noticed a loss of
sensation starting in both feet, progressing to her legs
and thighs; 1 year later she needed unilateral support
to walk and soon required a wheelchair. She later
developed anorexia, dysphagia, vomiting after meals,
constipation alternating with uncontrollable diarrhea
and urinary incontinence.
At age 70 the patient was visited for the first time.
She remained mainly bedridden and presented
severe tetraparesis and anesthesia of all sensation
types in the four limbs and the front of the trunk. She
had severe malnutrition and OH. A genetic study
was performed. At age 73 she died due to a respi-
ratory infection superimposed on severe cachexia.
Material and methods
Immunological studies
A direct ELISA with the monoclonal antibody
Mab39-44 was performed on the Spanish patient
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after LTX, to determine the presence or absence of
the variant.
Molecular studies
We studied DNA and plasma from two Spanish and
two Portuguese patients, one asymptomatic Spanish
relative, and three asymptomatic Portuguese relatives
(Figures 1 and 2).
SSCP analysis was performed on isolated genomic
DNA on exons 2, 3 and 4 of the TTR gene under
conditions previously described [7]. Exon 3 was
amplified with primers 3A (50-TCCTCCATGCG
TAACTTAAT-30) and 3B (50-ACTGTGCATT
TCCTGGAATG-30) using 30 cycles of 30 s at
928C, 1 min at 558C and 1 min at 728C and was
cycle sequenced using ABI’s Big Dye Terminators
and the automatic sequencer ABI Prism 377. For
restriction fragment length polymorphism (RFLP)
analyses with the enzyme Bsr I, polymerase chain
reaction (PCR)-amplified exon 3 of TTR was treated
with the enzyme and analyzed on a 4% agarose gel
stained with ethidium bromide, following procedures
previously described. For mass spectrometry ana-
lyses, plasma was immunoprecipitated with anti-
transthyretin antibody (DAKO) (4:1) and the
immunoprecipitated proteins were resolved by
SDS-PAGE and stained by Coomassie Blue; the
TTR band was excised from the gel and digested
with endoproteinase Lys-C. MALDI mass spectro-
scopic analysis was performed on a PerSeptive
Voyager mass spectrometer in the linear mode [8].
DNA from the proband was first subjected to
TTR-mutation scanning of exons 2, 3 and 4. The
pattern obtained was normal, except for exon 3 (not
shown).
Ethical standards
The ethical guidelines of the Helsinki Declaration of
the World Medical Association were observed.
Results
Immunological studies
The direct ELISA with Mab39-44 showed the
disappearance of the variant in plasma, which was
the goal of LTX.
Molecular studies
DNA sequencing analysis of exon 3 revealed A to C
transition in the first base of codon 50 normally
encoding a serine (Figure 3A), giving rise to an
arginine residue. The presence of this mutant
arginine was confirmed by peptide mapping and
mass spectrometry analysis. Thus, as shown in
Figure 3B, mass spectrometry analysis of TTR
peptides corresponding to residues 48–75 of the
polypeptide chain from a normal subject (labeled N)
shows the normal peptide of 3142 mass whereas the
proband (labeled P) shows an additional peptide of
3211 mass corresponding to the mutated peptide
consistent with the change in mass resulting from the
serine for arginine substitution.
The mutation abolishes a cleavage site for the
enzyme Bsr I and therefore RFLP analysis of the
proband DNA was performed and compared with
control DNA. As shown in Figure 3C, a band of 248
bps is observed in the proband (labeled P) which is
absent in control DNA (labeled N). RFLP analyses
were then used to identify additional carriers of the
Ser50Arg mutation in the present study.
We identified the mutation in the four patients and
one Portuguese relative who was an asymptomatic
carrier. The other four relatives, three Portuguese
and one Spanish, were non-carriers (see Figures 1
and 2).
Discussion
To our knowledge this is the second report on this
mutation in Caucasian patients and the fifth de-
scribed in the literature.
The first Japanese patient [2] was a man who
presented with PNP at age 39 years and the most
outstanding symptoms were severe weight loss and
weakness; he died aged 45 and a postmortem
examination was performed. The genetic study of
hepatocytes showed in one allele T to G transversion
in exon 3 of TTR gene which led to replacement of
Ser by Arg at position 50; he was thus heterozygous
for the aforementioned mutation.
The second Japanese patient [3] was a 43-year-old
man who started with FAP at age 41 presenting with
sexual impotence, progressive PNP in all four limbs,
cardiomyopathy with atrioventricular block which
required a pacemaker, and particularly severe OH,
responsible for bouts of postural syncope. He died
aged 46 and necropsy showed amyloid deposition in
several organs which were stained with anti-TTR
serum. In the DNA analysis from the patient and five
asymptomatic relatives (mother, sister and three
offspring) the aforementioned mutation was identi-
fied in the patient and one of the offspring, who also
were heterozygous.
At 48 years of age the French-Italian woman
patient [4] presented with constipation followed by
progressively severe diarrhea and sensorimotor syn-
drome in the lower limbs later followed by weakness
and loss of weight. Examination showed PNP, OH,
moderately impaired renal failure and hypertrophic
cardiomyopathy; she died around 54 years. In the
150 M. Munar-Que´s et al.
DNA analysis, the same mutation was found in one
allele, as in the Japanese patients.
The Vietnamese proband [5] was a 38-year-old
woman who presented with fatigue, stress-induced
dyspnea and chronic cough accompanied by weight
loss and constipation. Restrictive cardiomyopathy
due to amyloid deposition was suspected after echo-
cardiography, 99Tc-MDP scan, and cardiac cathe-
terization; amyloid was detected in gastric and rectal
biopsies and also in the left ventricle; no outcome
data were reported. The mutation was identified in
the proband, and three siblings (all female patients)
and also in five asymptomatic cousins (three women
and two men); no information was provided con-
cerning the molecular study or the clinical picture of
the three siblings.
Age at onset in both Portuguese patients (48 and
68 years) differs from the mean onset age of the
patients with TTRVal30Met (33.5 years). However,
onset age of the Spanish patients (40 to 53) is similar
to the mean onset age of TTRVal30Met patients
(45.7 years) [9].
In our patients (excepting the Spanish ancestor
with only vitreous amyloidosis) and in the three
previously described patients with PNP and other
systemic manifestations, the course of FAP was very
aggressive: multiple symptoms developed rapidly and
deterioration was progressive. We emphasize the
Spanish proband’s confinement to a wheelchair
due the OH severity, a finding not reported in
FAP patients. On the contrary the patient with
only vitreous amyloidosis, had slow progression of
Figure 3. (A) Sequence of exon 3 of the proband showing an A to C tranversion in the first base of codon 50. (B) Mass spectrometry analysis
of TTR peptides (residues 48–75) from a normal control (left) and from the proband (right). (C) RFLP analyses with BsrI on exon 3; N,
normal control DNA; P, proband DNA.
Novel base change for TTRSer50Arg 151
vitreous deposits and right and later left vitrectomy
were required. He died from lung cancer at 68, 15
years after the onset of FAP, without systemic
symptoms.
The Spanish proband is the first with this mutation
to undergo LTX. We consider that the result after 6
years is encouraging as he has shown significant
improvements. Based on the aforementioned aggres-
siveness of this mutation, LTX must be indicated in
the early first stages of the disease.
Genetic diagnosis identified the mutation in three
patients and one disease-free relative. The most out-
standing feature of DNA analysis was the single base
tranversion A to C in codon 50 (CGT instead of
AGT), whereas in both Japanese patients and the
French-Italian patient it was T to G (AGG instead of
AGT). To our knowledge only six FAP mutations
with more than one single nucleotide mutation for the
same codon have been reported to date: four in exon
2, Asp18Glu, Lys35Asn, Glu42Asp, and Gly47Arg;
and two in exon 3, Ile68Leu and Lys70Asn [1].
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